{"nct_id":"NCT04233216","title":"Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)","status":"COMPLETED","status_verified_date":"2024-12","start_date":"2020-03-18","start_date_type":"ACTUAL","primary_completion_date":"2022-11-21","primary_completion_date_type":"ACTUAL","completion_date":"2023-11-01","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}